Search clinical trials for: BAY 59-7939

Total 9042 results

Bayer

Completed

Bioequivalence Study of Rivaroxaban

Embolism, Atrial Fibrillation and Venous Thrombosis

Japan
Bayer

Completed

Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects

Embolism, Atrial Fibrillation and Venous Thrombosis

Japan
Bayer
Janssen Research & Development, LLC

Completed

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects

Clinical Pharmacology

Japan
Bayer
Janssen Research & Development, LLC

Completed

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects

Clinical Pharmacology

Japan
Bayer
Janssen Research & Development, LLC

Completed

Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation (XARENAL)

Non-valvular Atrial Fibrillation (NVAF)

Korea, Republic of
Bayer
Janssen Research & Development, LLC

Completed

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer (COSIMO)

Venous Thrombosis and Pulmonary Embolism

Italy, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Spain, Denmark, Australia
Bayer
Janssen Scientific Affairs, LLC

Completed

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study (XASSURE)

Stroke

China
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China (XAPEC)

Pulmonary Embolism

China
Bayer
Janssen Research & Development, LLC

Completed

Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study (X-PRESS)

Atrial Fibrillation

Taiwan
Bayer
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF) (XARIN)

Non-valvular Atrial Fibrillation (NVAF)

India
Janssen Research & Development, LLC
Bayer

Completed

A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

End-Stage Renal Disease

United States
Bayer

Completed

Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany

Venous Thromboembolism

Germany
Janssen Research & Development, LLC

Terminated

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection (PREVENT-HD)

Coronavirus Disease 2019 (COVID-19)

United States
Bayer
Janssen Research & Development, LLC

Completed

BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies

Atrial Fibrillation

Germany
Bayer
Janssen Scientific Affairs, LLC

Completed

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) (EinsteinChoice)

Thrombosis | Venous Thrombosis | Thromboembolism | Venous Thromboembolism | Pulmonary Embolism

Belgium, France, China, Switzerland, New Zealand, South Africa, Hungary, United States, Canada, Australia, Netherlands, Spain, Russian Federation, Austria, Mexico, Taiwan, Brazil, Czechia, Denmark, Germany, Israel, Italy, Korea, Republic... and more
Apitope International NV
Quintiles, Inc.; European Commission

Completed

ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy

Graves Disease

United Kingdom
Benjamin Viglianti

Recruiting

Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Group 1)

Hypertension | Cholesterol | Radiotracer

United States
Bayer

Completed

Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell

Canada, United States, Germany, United Kingdom, France, Netherlands
National Institute of Allergy and Infectious Diseases...

Completed

Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

Influenza

United States
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai Zhongshan Hospital

Active, not recruiting

A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors (CAR)

Soft Tissue Sarcoma | Gastric Cancer | Pancreatic Cancer | Solid Tumor | Bladder Cancer

China
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai Public Health Clinical Center

Active, not recruiting

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma

Renal Cell Carcinoma

China
Jiangsu Province Centers for Disease Control and...
Academy of Military Medical Sciences，Academy of Military Sciences，PLA ZHONGYIANKE...

Recruiting

Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)

COVID-19

China
Xijing Hospital

Unknown

Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events (TRACE)

Ischemic Stroke | TIA

China
Bayer

Active, not recruiting

Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and/or With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD)

Coronary Artery Disease (CAD) | Prevention of Atherothrombotic Events | Symptomatic Peripheral Artery Disease (Symptomatic PAD)

India
National Institute of Allergy and Infectious Diseases...

Terminated

B-19 Parvovirus Vaccine Study

Parvovirus B19 Infection

United States
Massachusetts General Hospital

Completed

Photobiomodulation in Autism Spectrum Disorder (ASD)

Autism Spectrum Disorder | Autism

United States
Jiangsu Province Centers for Disease Control and...
West China Hospital

Completed

A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)

COVID-19

China
National Institute of Allergy and Infectious Diseases...

Completed

gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females

Cytomegalovirus Infections

United States
University of Iowa
National Cancer Institute (NCI); Mayo Clinic; Pfizer

Completed

A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated

Chronic Lymphocytic Leukemia

United States
Stanford University
National Institutes of Health (NIH)

Withdrawn

Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.

Mycosis Fungoides
Bayer

Completed

To Evaluate Eye Installation-Tear Free

Sunscreening Agents

United States
AVIR Green Hills Biotechnology AG

Completed

Dose Finding Study of Single Dose GHB11L1 in Healthy Adults (GHB-CS07)

Influenza, Human

Austria
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Withdrawn

Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above

COVID-19

China
Pfizer

Completed

CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer

Carcinoma, Breast

United States
Janssen Research & Development, LLC
Harvard Medical School (HMS and HSDM); Bayer; Duke Clinical Research Institute

Completed

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome (GEMINI ACS 1)

Acute Coronary Syndrome

United States, France, Poland, Ukraine, Belgium, Spain, Argentina, Bulgaria, Russian Federation, Turkey, Japan, Canada, Netherlands, Korea, Republic of, Brazil, Australia, Hungary, Sweden, Czechia, Denmark
Pfizer

Completed

CPG 7909 in Patients Wih Stage IV Renal Cell Cancer

Carcinoma, Renal Cell
Children's Hospital Medical Center, Cincinnati
University of Cincinnati

Completed

Comparing Children's Books to Brochures for Safe Sleep and Infant Reading Education During Prenatal Care

Sudden Unexplained Infant Death | Child Rearing | Literacy

United States
Pfizer

Completed

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Melanoma | Carcinoma, Renal Cell | Breast Neoplasms | Carcinoma, Non-Small-Cell Lung | Lymphoma, T-Cell

United States, Germany
Pfizer

Completed

CPG 7909 in Patients With Cutaneous T-Cell Lymphoma

Lymphoma, T-Cell, Cutaneous
Bayer
Janssen Research & Development, LLC

Completed

Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention (X-PLORER)

Coronary Artery Disease | Cardiovascular Disease

Belgium, Netherlands
Centre Hospitalier Universitaire de Nice

Completed

Cholera Toxin B Subunit (CTB) Administered by Mucosal Way in Healthy Adult Volunteer

Infection

France
Istanbul University - Cerrahpasa (IUC)

Completed

Efficacy of A Novel in Prevention of Neonatal Hypothermia

Preterm Birth | Hypothermia | Newborn

Turkey
Ludwig Institute for Cancer Research

Completed

Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer

Prostate Cancer

Switzerland, Germany
Bayer

Completed

An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study

Venous Thromboembolism

United States, Canada
BTL Industries Ltd.

Completed

HIFEM for Arms, Lower Limbs, and Oblique Muscles

Muscle Tone Increased

United States
Bayer
Janssen Research & Development, LLC

Completed

Oral Rivaroxaban in Children With Venous Thrombosis (EINSTEINJunior)

Venous Thrombosis

France, United States, Switzerland, Netherlands, Canada, Germany, Austria, Australia, Israel, Italy
Ronald Levy
Pfizer

Completed

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

Lymphoma | Lymphoma, Non-Hodgkin | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell

United States
T3 Pharmaceuticals AG

Recruiting

First in Human Study of T3P-Y058-739 (T3P)

Advanced Solid Tumor

United Kingdom, Switzerland
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine

Malaria

United States
Ronald Levy
American Society of Clinical Oncology; Lymphoma Research Foundation

Completed

CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas

Mycosis Fungoides | Non-Hodgkin Lymphoma

United States

Search clinical trials for: BAY 59-7939

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations